Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.061
- Book/Share 15.3114
- PB 7.3634
- Debt/Equity 1.3022
- CurrentRatio 1.3693
- ROIC 0.1532
- MktCap 140862633200.0
- FreeCF/Share 7.9005
- PFCF 14.3095
- PE 23.6542
- Debt/Assets 0.4421
- DivYield 0.0344
- ROE 0.3171
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
| Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
| Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
| Initiation | GILD | Bernstein | -- | Outperform | -- | $105 | Oct. 17, 2024 |
| Upgrade | GILD | Wells Fargo | Equal Weight | Overweight | $78 | $100 | Oct. 7, 2024 |
News
Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Read More
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
During this time of heightened market volatility, it pays to be invested in the right places.
Read More
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Published: March 03, 2025 by: Reuters
Sentiment: Negative
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
Read More
Why Gilead Sciences Remains A Buy After A 40% Rally
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year.
Read More
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment o.
Read More
GILD or VRTX: Which Is the Better Value Stock Right Now?
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Calls of the Day: Gilead Sciences and Merck
Published: February 18, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the Calls of the Day in two biotech names.
Read More
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.
Read More
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Published: February 12, 2025 by: Benzinga
Sentiment: Positive
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.
Read More
Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - CFO Cindy Perettie - EVP, Kite Conference Call Participants Geoff Meacham - Citigroup Terrence Flynn - Morgan Stanley Tim Anderson - Bank of America Umer Raffat - Evercore ISI Michael Yee - Jefferies Daina Graybosch - Leerink Partners Mohit Bansal - Wells Fargo Brian Abrahams - RBC Capital Markets Tyler Van Buren - TD Cowen …
Read More
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Markets Mixed on Powell Testimony, Q4 Earnings
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Tuesday, February 11, 2025 Market indexes were mixed today, after seeing all the majors in the red before the opening bell. The Dow closed up +123 points, +0.28%, while the S&P 500 squeaked by +2 points.
Read More
Gilead Sciences Beats Q4 EPS Forecast
Published: February 11, 2025 by: The Motley Fool
Sentiment: Positive
Gilead Sciences (GILD 0.69%), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated $1.74.
Read More
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Uber, Comcast, Gilead Sciences and Onfolio Holdings are included in this Analyst Blog.
Read More
3 Fabulous Dividend Stocks to Buy in February
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel P. O'Day
- Employees 17600